Your session is about to expire
← Back to Search
Ketone Esters for Obesity and Insulin Resistance
Study Summary
This trial tests if a ketone supplement can reduce appetite and improve cognition, metabolism & cardiovascular function for those with obesity & insulin resistance.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are applicants above eighty-five years of age being considered for this trial?
"This trial is seeking participants of ages 18-50 years."
What are the eligibility requirements for participation in this research?
"The criteria for enrolment in this medical clinical trial is impaired glucose tolerance and an age bracket between 18-50. Approximately 30 individuals are anticipated to join the study."
Are there openings left in this scientific experiment?
"Affirmative. According to the clinicaltrials.gov records, this study is presently recruiting applicants and was initially posted on December 20th 2022. The most recent update occurred on December 6th of that same year, with 30 patient slots available at a single centre."
How many individuals are partaking in this research endeavor?
"Affirmative. The clinical trial is open to new participants based on the data hosted on clinicaltrials.gov, which states that it was first posted in December 20th 2022 and last edited 6 days later. 30 individuals have been invited to join the study at one medical centre."
What aims does this medical experiment seek to accomplish?
"The primary evaluation metric of this trial, measured over a defined period post ingestion, is Thirst - Visual Digital Analog Scale (0-100). Supporting metrics include Prefrontal Cortex Oxygenation as indicated by Near-infrared spectroscopy, Peripheral Vascular Conductance estimated through Blood flow normalized to blood pressure readings (mL/min/mmHg), and finally capillary Blood glucose levels."
Share this study with friends
Copy Link
Messenger